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� The best surgical approach for PTMC is still object of debate.
� Hemithyroidectomy may be adequate for low-risk patients, with no need for routine completion thyroidectomy.
� Total thyroidectomy or completion thyroidectomy is rather indicated in selected patients with risk factors for mortality and recurrence.
� Accurate patient selection is important to achieve the best results.
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a b s t r a c t
Aim: Papillary thyroid microcarcinoma (PTMC) is increasing in incidence. Despite its excellent clinical
outcomes, there is still debate regarding which surgical approach is more appropriate for PTMC, pro-
cedures including hemithyroidectomy (HT), total thyroidectomy (TT), and completion thyroidectomy
(CT) after initial HT and histopathologic examination conﬁrming a PTMC. Here we report our experience
in the surgical management of PTMC.
Methods: We conducted a retrospective evaluation of all patients who received a postoperative diagnosis
of PTMC between January 2001 and January 2016. Every patient was divided according to the type of
surgery performed (TT or HT alone). Follow-up consisted of regular clinical and neck ultrasonographic
examination. Clinical and histopathological parameters (e.g. age, sex, lesion size, histological features,
multifocality, lymph node metastases, BRAF status when available) as well as clinical outcomes (e.g.
complications rates, recurrence, overall survival) were analyzed.
Results: Group A consisted of 86 patients who underwent TT, whereas Group encompassed 19 patients
who underwent HT. Mean follow-up period was 58.5 months. In Group A, one patient (1.2%) experienced
recurrence in cervical lymph nodes with need for reoperation. In Group B, eight patients (42%) under-
went completion thyroidectomy after histopathological examination conﬁrming PTMC, while one patient
(5.3%) developed PTMC in the contralateral lobe with need for reoperation at 2 years after initial surgery.
Multifocality was found in 19 patients in Group A (22%). Of these, 14 presented bilobar involvement,
whereas in 3 cases multifocality involved only one lobe. 1 patient in Group B (5.3%) presented with
unilateral multifocal PTMC (p ¼ 0.11).
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2Conclusions: Low-risk patients with PTMC may beneﬁt from a more conservative treatment, e.g. HT
followed by close follow-up. However, appropriate selection of patients based on risk stratiﬁcation is the
key to differentiate therapy options and gain better results.
© 2017 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd.
1. Introduction
Papillary thyroid carcinoma (PTC) accounts for about 80e90% of
all thyroid cancers and its incidence has been increasing in the last
three decades worldwide [1]. According to the American Cancer
Society, about 64,300 new cases were estimated to be diagnosed in
2016 [2,3]. In Italy, PTC is the second most frequent cancer in
women below 45 years of age and its incidence has almost doubled
between 1991e1995 and 2001e2005 [3,4]. Despite this growth in
incidence, mortality rate has remained the same (0.5 death per
100,000) and long-term prognosis is usually excellent, with 10-year
survival rates up to 98% [3,5e7]. This upward trend in incidence can
be easily explained by the wide availability and use of both neck
ultrasonography and ﬁne-needle aspiration cytology (FNAC), which
allow an increased detection of papillary thyroid cancersmeasuring
1 cm or smaller, the so-called papillary thyroid microcarcinomas
(PTMCs) [8e11]. Papillary carcinoma represents the most common
type of thyroid carcinoma in patients >45 years old [2,8e11] and
PTMC accounts for 49% of the overall increased incidence in thyroid
cancer, as reported by the Surveillance Epidemiology and End Re-
sults (SEER) database [8,10]. PTMCs are also frequently identiﬁed
incidentally upon histopathological examination of surgical speci-
mens from presumed benign thyroid disease.
However, since PTMC generally exhibits an overall excellent
prognosis, the most appropriate management of this disease re-
mains a matter of debate and strategies range from observation
alone [12] to surgical resection [13,14]. Still, there is no consensus
yet about the extent of surgery ensuring oncologic completeness
and low risk of complications and surgical approaches may consist
of either simple lobectomy or total thyroidectomy, sometimes
associated with neck dissection and/or postoperative radioactive
iodine (RAI) therapy [6,9,15e21].
In order to better clarify whether the extent of surgery affects
the outcomes of PTMC patients, we aimed to evaluate patients
undergoing total thyroidectomy versus those undergoing simple
hemithyroidectomy by comparing complications, reoperation
rates, and overall survival.
2. Materials and methods
A retrospective analysis was carried out considering all papillary
thyroid cancer operations performed at the General Surgery
Department of the University Hospital of Treiste between January
2001 and January 2016. 105 consecutive patients with histological
diagnosis of PTMC (major diameter  10 mm) were enrolled in the
study and assigned to two independent groups according to
whether they received total thyroidectomy (TT, Group A) or hem-
ithyroidectomy (HT, Group B). Preoperative work-up consisted of
full clinical examination, ultrasonography of the thyroid gland and
regional lymph nodes, and FNAC. In most cases, PTMC was diag-
nosed preoperatively on FNAC analysis. In a minority of cases,
diagnosis was incidental on pathological specimens after surgery
for presumed benign thyroid disease. Patients with preoperative
evidence of lymph node disease, those with extrathyroidal exten-
sion at clinical and/or ultrasound examination, and papillary tu-
mors larger than 1 cm were not included in the analysis.
Total thyroidectomy (TT) was immediately performed in case of:
malignant or suspicious lesions (TIR 5 or TIR 4 on FNAC) of10mm
in diameter at preoperative ultrasound (US), multifocal PTC, bilat-
eral goiters, prior neck irradiation, history of familial thyroid ma-
lignancies, age > 45 years, and/or presence of BRAF and/or nRAS
mutation (when available) [22]. When nodal metastases were
identiﬁed at the time of surgical procedure or during follow-up, the
patients underwent either unilateral or bilateral central neck
dissection (CND) or lateral neck dissection (LND) according to the
American Thyroid Association (ATA) guidelines [23].
Patients were considered to be “low-risk” when presenting
<2 cm papillary thyroid cancer without preoperatively apparent
cervical lymph node metastases. Patients were classiﬁed as “high-
risk” when unfavourable histological features (i.e. tall cells, onco-
genic mutations as BRAF or nRAS, vascular invasion), extrathyroidal
extension or spread of the cancer to the neck lymph node with
potential risk factors (i.e. sex, age, and familiarity) were present
[22e24].
HT was the treatment of choice for patients with preoperative
TIR2 or TIR3 diagnosis [25], monolateral, unifocal, and intra-
thyroidal lesions, negative BRAF and/or nRAS status on FNAC, no
history of previous head and neck irradiation, no clinical nor
radiological evidence of nodal disease or distant metastases, no
other speciﬁc risk factors. HT group included also 6 cases with BRAF
negative, TIR 4 lesions (i.e. suspicious for malignancy), who un-
derwent HT alone by choice of the single patients. Completion
thyroidectomy (CT) was performed when deﬁnitive pathology
found one or more of the following features associated with
potentially aggressive PTMCs: multifocal disease with an overall
sum of all lesions' diameters > 10 mm, actual size of papillary
thyroid carcinoma >10 mm at deﬁnitive histology, microscopic
extrathyroid extension, aggressive features (tall cell, columnar cell,
or diffuse sclerosing variants).
Radioactive iodine (RAI) ablation therapy was administered on
the basis of stage and prognostic risk factors [23e27]. In detail,
patients received RAI therapy after total thyroidectomy or
completion thyroidectomy in case of: aggressive histological sub-
types (i.e. tall cells, columnar cells, or diffuse sclerosant variants),
multifocality, extrathyroid invasion, and lymph node metastases,
which potentially increase the risk for local recurrence and me-
tastases. Successful thyroid ablation was deﬁned by the disap-
pearance of any visible area of uptake in the thyroid bed (1%), and
undetectable serum Tg levels of levothyroxine (TSH > 30mUI/mL).
All patients in Group An underwent long-term follow-up every
6 months for the ﬁrst two years and on a yearly basis thereafter,
whereas patients in Group B were followed every 6 months for the
ﬁrst three years and every year thereafter. Every follow-up visit
consisted of clinical examination, cervical US, measurement of
serum thyroglobulin (Tg) levels and anti-thyroglobulin antibodies
(Ab-Tg).
Recurrence was deﬁned by the presence of thyroid carcinoma
within the thyroid bed, regional lymph nodes metastates, distant
site metastases, or, in Group B patients, lesions to the contralateral
lobe.
Histopathologic data (e.g. multifocality, aggressive features,
extracapsular invasion, lymph node metastases) were recorded for
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tion thyroidectomy or total thyroidectomy were appropriate or
should have been considered an overtreatment.
2.1. Statistical analysis
The statistical analysis was performed with GraphPad Software
and by using Chi-squared test or Fisher's exact test, when appro-
priate. A p-value less than 0.05 was considered statistically
signiﬁcant.
3. Results
Analyzed data and results are summarized in Table 1. A total of
105 patients with PTMC underwent surgery over a 15-year period.
Group A consisted of 86 patients (81.9%), 66 women and 20 men,
mean age 54 years (range 12e77 years), who underwent TT. Group
B consisted of 19 patients (18.1%), 14 women and 5 men, mean age
56 years (range 30e79 years), who underwent HT. 64 patients
(61%) presented with TIR 4 or TIR 5 lesions, whereas 41 patients
(39%) presented with TIR 2 or TIR 3 lesions on preoperative cyto-
logical diagnosis, respectively.
Multifocality was found in 19 patients in Group A (22%). Of
these, 14 (16.3%) presented bilobar involvement, whereas 3 cases
presented with unilateral multifocal PTMC. In Group B, 1 patient
(5.3%) presented with multifocal unilobar PTMC (p ¼ 0.11).
Mean tumor size was 6 mm (range 1e10 mm) in Group A and
5.3 mm in Group B (range 1e10 mm) (p ¼ ns). BRAF mutation was
tested preoperatively only in a minority of cases (n ¼ 16 patients)
and resulted positive in 9 patients with either TIR 3 or TIR 4 cyto-
logical diagnosis.
Either unilateral or bilateral central neck dissection (CND) was
performed in 24 patients in Group A (27.9%) due to suspicious
lymph nodes determined intraoperatively. Central nodal metasta-
ses were reported in 14 patients (58.3%).
8 patients out of 19 (42.1%) in group B underwent completion
thyroidectomy at a mean time of 30 days after initial surgery on the
basis of deﬁnitive histology. Reasons for completion thyroidectomy
included: evidence of microscopic extrathyroid extension of tumor
(n ¼ 2 patients), multifocal unilateral disease (n ¼ 1 patient),
aggressive histopathologic variants (n ¼ 1 patient with tall cells
PTMC, n ¼ 1 patient with diffuse sclerosing PTMC). Three patients
required completion thyroidectomy after HT for personal prefer-
ence on the basis of perceived risk of recurrence.
Mean follow-up period was 58.5 months (range 6e128 months)
and consisted of regular physical examination and neck US
imaging.
No signiﬁcant difference was found between the two groups in
terms of recurrence rates (p ¼ 0.33). One patient in Group A (1.2%)
developed regional lymph node recurrence 7 months after surgery
and required a central and lateral neck dissection. To date, this
patient is still alive and disease-free.
Morbidity rateswere not signiﬁcantly different between the two
sets of patients, although incidence was slightly higher in the TT
group (16.3% in group A vs. 10.5% in group B, respectively;
(p ¼ 0.73). Transient nerve palsy was reported in 4 cases (4.6%) in
Group A and 1 case in Group B (5.3%), respectively (p ¼ 0.68).
Transient hypoparathyroidism, deﬁned by serum Calcium levels
<8.5 mg/dL), was recorded in 9 patients in Group A (10.4%) and in 1
patient in Group B (5.3%), respectively (p ¼ 0.18). Permanent nerve
damage was found only in 1 patient in Group A (1.2%, p ¼ 1.00),
whereas permanent hypoparathyroidism was not reported in any
group.
The one patient in Group A who required further surgery for
nodal recurrence suffered from transient hypoparathyroidism,
whereas no complications occurred in Group B patients requiring
completion thyroidectomy.
Postoperative RAI therapy was performed in 37 patients out of
86 in Group A (43%) and in 7 patients out of 10 in Group B after
completion thyroidectomy (70%). The mean time-interval between
thyroidectomy and 131I administration for postsurgical remnant
ablation was 3,5 months.
Mean disease-free survival was 72 months (range 6e192
months) in Group A and 78months (range 8e137months) in Group
B, whereas the 5-year disease free survival was 98.8% and 93.7%
respectively (p ¼ 0.33). During the study period, 8 patients died for
causes unrelated to thyroid cancer. In Group A, 3 patients died
because of other cancers (lung cancer, gastric cancer, and chol-
angiocarcinoma, respectively) and 4 died for cardiovascular events,
96, 17, 83, 36, 58, 94 and 101months after TT, respectively. In Group
B, 1 patient died for a stroke at 137 months after HT. No PTMC-
related death was recorded during the follow-up period.
Table 1
Age, sex, tumor features, pathologic ﬁndings and outcome in two groups of patients.
Group A (TT) Group B (HT) p value
Number of patients (%) 86 (81.9%) 19 (18.1%) <0.0001
Mean age (range) 54 (12e77) 56 (30e79) -
Sex (M:F) 20:66 5:14 ns
Mean follow-up months (range) 57 (6e154) 64 (12e168) ns
Mean tumor size in mm (range) 6 (1e10) 5.3 (1e10) ns
Multifocal PTMC (%) 19 (22%) 1 (5.3%) 0.11
Bilateral PTMC (%) 14 (16.3%) 0 ns
Aggressive variants (%) 7 (8.1%) 2 (10.5%) ns
Extrathyroid invasion (%) 11 (12.8%) 2 (10.5%) ns
Lymph node metastases/lymph node dissection (%) 14/24 (58.3%) 0/0 e
Morbidity rates 16,3% 10.5% 0.73
Reoperation (%) 1 (1.2%)a 9 (47.3%)b <0.0001
Transient nerve palsy (%) 4 (4.6%) 1 (5.3%) 0.68
Transient hypoparatiroidism (%) 9 (10.4%) 1 (5.3%) 0.18
Permanent nerve palsy (%) 1 (1.2%) 0 1.00
Permanent hypoparatiroidism (%) 0 0 /
Recurrence rate (%) 1 (1.2%) 1 (5.3%) 0.33
Disease free survival (range) 72 (6e192) 78 (8e137) ns
5-year disease free survival 98.8% 93.7% 93.7% 0.33
Abbreviations: * TT ¼ Total thyroidectomy; HT¼ Hemithyroidectomy.
a 1 lymph node metastases.
b 2 cases of PTMC in the controlateral lobe found at ﬁnal pathology, no pathologic ﬁndings in the other specimens.
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44. Discussion
Papillary thyroid microcarcinoma (PTMC) is increasing in inci-
dence, partly due to increased detection determined by even more
sensitive imaging techniques. However, both morbidity and mor-
tality rates of thyroid cancer have not increased, suggesting that the
upward trend in incidence more likely reﬂects an increased
detection of subclinical disease which was previously discovered
only casually on autopsy [8,26,27].
Prognosis is generally excellent, with 10-year survival rates of
90e95%. However, the best surgical management for PTMC is not
established yet. ATA latest management guidelines [23] suggest
that hemithyroidectomy in patients with PTMCmay be appropriate
treatment. Nonetheless, others Authors support only strict clinical
observation [12]. Lin et al. [28], in a series of 7818 patients with
PTMC, reported overall survival rates at 10 and 15 years of 96.6%
and 96.3%, respectively, and a disease-speciﬁc survival of 99.9%. Yu
et al. [29] achieved similar good results analyzing 18,445 patients
with PTMC treated between 1988 and 2007, with 10 and 15-year
overall survival of 94.6% and 90.7%, respectively, and disease-
speciﬁc survival of 99.5%. These ﬁndings are supported by the
meta-analysis of Roti et al. [30], who reviewed 17 series of PTMC
reporting an overall distant recurrence rate of 0.37% and a cancer-
related death of 0.34%.
The present study aimed to assess the most appropriate surgical
management for PTMC patients, considering as primary goals the
completeness of resection associated with acceptable morbidity
risk, accurate tumor staging and adequate follow-up. In our study,
we tried to determine whether immediate TT could be considered
appropriate treatment compared to HT and whether CT was
required after initial HT. In particular, we analyzed how many pa-
tients in the TT group presented on histopathologic examination
multifocality lesions involving the contralateral lobe and/or
aggressive features and/or extracapsular invasion and/or lymph
node metastases. We further tried to determine in how many pa-
tients treated by means of a TT for a PTMC a simple HT could have
been considered sufﬁcient and adequate treatment. Last but not
least, we evaluated the results of histopathological examination of
the contralateral lobectomy in patients undergoing completion
thyroidectomy, in order to determine whether the procedure rep-
resented an overtreatment.
The retrospective nature of the present study is a known po-
tential bias. Obviously, it is important to differentiate patients
diagnosed with PTMC preoperatively from those diagnosed after
initial HT.
But, I underline, that the treatment option probably should be
no different. In fact, until 2015 our local protocols, in accordance
with our endocrinologists, (perhaps wrongly or maybe doing an
overtreatment) suggested TT as a treatment of choice for all PTC
(FNAC demonstrating malignancy) independently from size and
localization (unilobar vs bilobar). The same local guidelines pro-
posed HT for all patients with unilobar benign or indeterminate
cytology (TIR 2 and 3). In case of thyroid cancer on deﬁnitive his-
tology, CT was then proposed independently from the presence of
extrathyroid extension or other acknowledged major risk factors.
On the basis of ATA revised guidelines and availability of germline
mutation assessment of BRAF and nRAS on FNAC, our local policy
was updated after January 2015. To date, low-risk PTMC patients
are proposed to undergo HT and, of course, to avoid a completion
thyroidectomy in case of malignancy, discovered postoperatively, in
absence of risk factors acknowledged risk factors.
Another limitation of the present study is the small sample size,
hindering us to draw any deﬁnitive conclusion. Moreover, certain
risk factors, as histological features, vascular invasion, extra-
thyroidal extension, and spread to regional lymph nodes, are
difﬁcult to estimate preoperatively. But, in all patients, other po-
tential risk factors, i.e. sex, age, familiarity, BRAFV600E mutation
status (when available), are evaluable preoperatively ant the
extrathyroidal extension of tumor and/or the presence of suspi-
cious lymph nodes are evident in most cases at the time of surgery.
According to the latest ATA Guidelines [23], HT should be
considered the treatment of choice for PTMC patients. However,
several Authors [12,31,32] now advocate clinical observation for
these tumor considering the demonstrated indolent course of this
tumor. Thus, the question of CT versus HT is possibly not worth
asking and current guidelines suggest that CT for PTMC would not
be indicated unless there is a history of head and neck irradiation
and/or in presence of strong family history [23]. Nonetheless, the
purpose of the study was to retrospectively evaluate our personal
experience trying to determine whether immediate TT and CT after
HT were to be considered appropriate surgical management of
PTMC patients.
Another concern is represented by the fact that the study design
is somewhat ﬂawed since the two groups presenting different
preoperative characteristics (i.e FNAC, and other speciﬁc risk fac-
tors) and different interventions were employed based on high or
low risk characteristics. However, the analysis was retrospective in
nature and data were collected on the basis of postoperative
deﬁnitive histology (demonstrating PTMCs in both groups), thus
enabling us to compare the two sets of patients.
Themost interesting question that needs to be answered is what
risk factors (molecular or demographic) are predictive of recur-
rence or multifocality in PTMCs, where a TT should be performed
initially to avoid re-operation in a hostile surgical ﬁeld. According
to literature data, hereditary conditions, gender (Women are
diagnosed with 3 of every 4 thyroid cancers), age (<45 years), and
oncogenic mutation (BRAF/nRAS) on FNAC, can be predictive of
recurrence or multifocality in PTMCs. Other factors that may be
taken into account and be further analyzed could include low-
iodine diet, radiation exposure, race (Caucasians and Asians are
more likely to develop thyroid cancer), and association with breast
cancer [22e24,33].
In literature, conﬂicting data have been reported with regard to
the extent of surgery in order to ensure oncologic completeness.
Hemithyroidectomy generally presents lower complication rates
and determine a minimal impact on patient's life, allowing for the
preservation of thyroid functions by avoiding the need for substi-
tutive hormonal therapy in about 30e40% of cases [23,34,35].
However, HT present the risk for reoperation to the controlateral
lobe after deﬁnitive histology and follow-up is usually limited
because of the impossibility to perform radioiodine therapy and to
check Tg levels.
Total thyroidectomy is a more radical surgical procedures which
allows for: 1) a complete removal of the tumor, especially for
multifocal/bilateral disease, with lower local recurrence, 2) an ac-
curate staging of the disease, and 3) the possibility to both detect
and treat any local or distant recurrence bymeans of RAI and serum
Tg levels. This surgical approach has been corroborated by Baudin
et al. and other more recent studies [36e39], which demonstrated
that total thyroidectomy reduces the risk of recurrence and
apparently improves survival rates. However, there is no deﬁnitive
evidence in literature regarding the improvement in both recur-
rence and survival rates in low-risk patients treated with more
aggressive approaches other than lobectomy [27,31,40e43].
Conversely, some authors believe these patients are being over-
treated and exposed to higher risks of complications [44]. A recent
large study analyzing data from the National Cancer Data Base
between 1985 and 1998, for a total patients of 12,469 with PTMC,
conﬁrmed these remarks by demonstrating that the extent of sur-
gery did not impact on recurrence nor on survival (p ¼ 0.24 and
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other studies, including Hay et al. (on 900 patients treated during a
60-year period) [31], Lee et al. (on 2014 patients treated for PTMC
between 1986 and 2006) [41], Lin et al. (on 7818 patients) [28] and
Ito et al. (on 2638 patients) [42]. Siassakos et al. [43] also reported
no recurrences or deaths during a 6-year follow-up after HT for
incidentally diagnosed PTMC patients.
Considering the indolent course of the disease, management of
PTMC is still debated and recent proposals include close observa-
tion without surgical treatment [12,31,32]. Ito et al. [42] prospec-
tively followed up a large group of PTMC patients who did not
undergo any intervention and they concluded that these patients
did not show a poorer prognosis when compared to those surgically
treated. Additionally, a more recent observation trial by the same
author showed that only 6.7% of low-risk PTMC ultimately become
enlarged during a 5-year follow-up [45].
All these data substantiate the hypothesis that PTMC probably
does not require an aggressive surgical management, which, on the
contrary, may determine overtreatment and unnecessary
morbidity. The present study is in accordance with these conclu-
sion. We conﬁrmed the benign course of PTMC after a mean follow-
up period of 58.5 months, during which both groups presented
excellent results in terms of disease-free and disease-speciﬁc sur-
vival, and no disease-speciﬁc deathwas observed. The study did not
yield statistically signiﬁcant differences in survival, recurrence and
complication rates between the two groups, even if surgical com-
plications occurred more frequently following total thyroidectomy
than hemithyroidectomy. In our case series, one patient (5.3%) of
Group B developed transitory hypoparathyroidism deﬁned by cal-
cium serum levels as lowas 8.5mg/dL at postoperative day one. The
above mentioned patient was asymptomatic and required oral
substitutive therapy for 48 h. No deﬁnitive hypocalcemia requiring
long-life substitutive treatment was recorded.
The lack of differences in recurrence or survival between the
two groups is in agreement with ﬁndings from other large series
and recent guidelines suggest there is no need for completion
thyroidectomy in low-risk patients, for whom close follow-up may
be adequate. Nevertheless, for those high-risk PTMC cases which
are more likely to recur and exhibit a worse prognosis compared
with low-risk PTMCs, aggressive strategies should be indicated.
Many studies have emphasized the need for a patient stratiﬁcation
based on the analysis of possible risk factors for mortality and
recurrence (e.g. extrathyroidal invasion, aggressive histological
subtypes, lymph node involvement, multifocality), in order to
determine the most appropriate treatment by maximizing the
beneﬁts of surgery [29,42,46,47]. In fact, the vast majority of PTMC
remain quiescent, causing no symptoms or threat to life. On the
contrary, there are other situations where central lymph node
metastases(CLNM) are described. Some tumor characteristics that
are used to predict the CLNM and that justiﬁed a TT to PTMC pa-
tients. YI-Li Zhou et al. [48] reported in their series that CND needs
to be considered in PTMC male patients, aged <50 years, or foci
>7 mm based on preoperative US. Also in our series we founded a
relatively high percentage of patients with preoperative diagnosis
of simple PTMC who presented at the surgical exploration, central
neck lymph nodes involvement (16.3%).
Another important aspect of PTCs is their multifocality. The
multifocality is heterogeneous and it can involve either a single
thyroid lobe or both. As reported by Anulekha Mary John et al. [49]
in his retrospective study where a multifocal tumor was found in
the 44,1% of the patients where 19,5% of multifocal disease was
restrict to a single lobe. On the contrary, in other previous studies
the incidence of bilateral PTMC reported is approximately 10e30%
[9e11].
In our study, we found 16.3% of bilateral PTMC in group A
whereas any patients of group B underwent completion thyroid-
ectomy presented a contralateral papillary carcinoma on ﬁnal his-
topathologic examination.
Based on our ﬁndings hemithyroidectomy would be maybe
sufﬁcient for low risks PTCs patients if followed by periodic follow
up and ultrasound and after accurate selection.
5. Conclusions
In conclusion, the results of the present study do not support the
routine TT in the treatment of PTMC patients while it is in accord
with the latest ATA Guidelines suggesting to perform for “low-risk”
PTMC the hemithyroidectomy. The risk for postoperative compli-
cation is signiﬁcantly increased in TT patients, without clear evi-
dence of reduction in recurrence or added beneﬁt survival.
Therefore, a less aggressive treatment may be adequate for most
PTMCs, with no need for routine completion thyroidectomy.
Although the best surgical approach for PTMC has to be adequately
tailored, a careful patient selection is of paramount importance to
determine the best treatment for each patient and achieve the
better results. More prospective studies with longer follow-up
periods are needed to further clarify the extent of surgery for
PTMC and to recognize what risk factors (molecular or de-
mographic) are predictive of recurrence or multifocality in PTMCs,
where a total thyroidectomy should be performed initially to avoid
re-operation in a hostile surgical ﬁeld.
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